Ligand Pharmaceuticals, Inc. (LGND)
285.03
-4.22
(-1.46%)
USD |
NASDAQ |
Sep 11, 15:41
Ligand Pharmaceuticals Gross Profit (TTM) : 244.88M for June 30, 2026
Gross Profit (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 244.88M |
| March 31, 2026 | 228.96M |
| December 31, 2025 | 220.83M |
| September 30, 2025 | 203.97M |
| June 30, 2025 | 141.51M |
| March 31, 2025 | 135.42M |
| December 31, 2024 | 123.10M |
| September 30, 2024 | 109.53M |
| June 30, 2024 | 89.64M |
| March 31, 2024 | 75.86M |
| December 31, 2023 | 88.05M |
| September 30, 2023 | 90.18M |
| June 30, 2023 | 105.44M |
| March 31, 2023 | 118.24M |
| December 31, 2022 | 106.10M |
| September 30, 2022 | 121.77M |
| June 30, 2022 | 126.86M |
| March 31, 2022 | 140.09M |
| December 31, 2021 | 154.81M |
| September 30, 2021 | 164.82M |
| June 30, 2021 | 154.88M |
| March 31, 2021 | 142.38M |
| December 31, 2020 | 129.68M |
| September 30, 2020 | 86.76M |
| June 30, 2020 | 73.25M |
| Date | Value |
|---|---|
| March 31, 2020 | 62.20M |
| December 31, 2019 | 76.34M |
| September 30, 2019 | 126.46M |
| June 30, 2019 | 146.83M |
| March 31, 2019 | 213.36M |
| December 31, 2018 | 229.32M |
| September 30, 2018 | 220.90M |
| June 30, 2018 | 210.71M |
| March 31, 2018 | 149.49M |
| December 31, 2017 | 123.61M |
| September 30, 2017 | 111.44M |
| June 30, 2017 | 101.07M |
| March 31, 2017 | 92.80M |
| December 31, 2016 | 92.76M |
| September 30, 2016 | 80.51M |
| June 30, 2016 | 78.46M |
| March 31, 2016 | 78.15M |
| December 31, 2015 | 65.51M |
| September 30, 2015 | 64.20M |
| June 30, 2015 | 61.82M |
| March 31, 2015 | 55.42M |
| December 31, 2014 | 55.40M |
| September 30, 2014 | 49.83M |
| June 30, 2014 | 46.82M |
| March 31, 2014 | 45.76M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Johnson & Johnson | 66.63B |
| Eli Lilly & Co. | 66.44B |
| Merck & Co., Inc. | 48.01B |
| Zevra Therapeutics, Inc. | 128.53M |
| Liquidia Corp. | 416.18M |